Carbon monoxide inhalation - Mallinckrodt

Drug Profile

Carbon monoxide inhalation - Mallinckrodt

Alternative Names: Covox

Latest Information Update: 04 Sep 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Ikaria Holdings
  • Developer Mallinckrodt plc
  • Class Inorganic carbon compounds
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Renal transplant rejection
  • New Molecular Entity No

Highest Development Phases

  • Discontinued Renal transplant rejection

Most Recent Events

  • 16 Apr 2015 Ikaria Holdings has been acquired by Mallinckrodt plc
  • 28 Jul 2008 Carbon monoxide inhalation receives Orphan Drug status for Renal transplant rejection in USA
  • 15 Feb 2008 Phase-II clinical trials in Renal transplant rejection in USA (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top